{
    "clinical_study": {
        "@rank": "105771", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "subcutaneous daily injection"
            }, 
            {
                "arm_group_label": "liraglutide", 
                "arm_group_type": "Active Comparator", 
                "description": "subcutaneous daily injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the effects of liraglutide (a drug used to treat\n      type 2 diabetes) on glucose (sugar) control over the 52 week study period when used in\n      addition to insulin."
        }, 
        "brief_title": "Liraglutide In Overweight Patients With Type 1 Diabetes", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Overweight"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1) Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII; also known as\n        insulin pump) or multiple (four or more) injections of insulin per day. 2) Using a\n        continuous glucose monitoring device (CGM) or regularly measuring their blood sugars four\n        times daily. 3) HbA1c of less than 8.5%. 4) Well versed with carbohydrate counting. 5) Age\n        18-75 years 6) BMI\u2265 25kg/m2 7) Age at diagnosis of type 1 diabetes should be <30 years. 8)\n        evidence of auto-immunity to beta cells (GAD-65 and islet cell antibody screen)\n\n        Exclusion Criteria:\n\n        1)Type 1 diabetes for less than 6 months; 2)Coronary event or procedure (myocardial\n        infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in\n        the previous four weeks; 3)Hepatic disease (transaminase > 3 times normal) or cirrhosis;\n        4)Renal impairment (serum eGFR <30ml/min/1.73m2); 5)HIV or Hepatitis B or C positive\n        status; 6)Participation in any other concurrent clinical trial; 7)Any other\n        life-threatening, non-cardiac disease; 8)Use of an investigational agent or therapeutic\n        regimen within 30 days of study. 9) history of pancreatitis 10) pregnancy 11) inability to\n        give informed consent 12) history of gastroparesis 13)history of medullary thyroid\n        carcinoma or MEN 2 syndrome. 14) Smokers will be advised not to change their amount of\n        smoking for the duration of the study; 15) Use of any agent other than insulin for\n        treatment of diabetes (metformin, pramlintide or thiazolidinediones."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753362", 
            "org_study_id": "1965"
        }, 
        "intervention": [
            {
                "arm_group_label": "liraglutide", 
                "intervention_name": "liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Glucagon-Like Peptide 1"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 15, 2013", 
        "location": [
            {
                "contact": {
                    "email": "sdhindsa@kaleidahealth.org", 
                    "last_name": "sandeep dhindsa, MBBS", 
                    "phone": "716-626-7998"
                }, 
                "facility": {
                    "address": {
                        "city": "Williamsville", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14221"
                    }, 
                    "name": "SUNY at UB, 115 flint road,"
                }, 
                "investigator": {
                    "last_name": "paresh dandona, mbbs", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "swilliams3@kaleidahealth.org", 
                    "last_name": "Sonja Williams", 
                    "phone": "716-626-7998"
                }, 
                "facility": {
                    "address": {
                        "city": "Williamsville", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14224"
                    }, 
                    "name": "diabetes endocrinology center of WNY"
                }, 
                "investigator": {
                    "last_name": "Paresh Dandona, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES", 
        "overall_contact": {
            "email": "sdhindsa@kaleidahealth.org", 
            "last_name": "sandeep dhindsa, MBBS", 
            "phone": "716-626-7998"
        }, 
        "overall_official": {
            "affiliation": "SUNY UB", 
            "last_name": "Paresh Dandona, MBBS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the study is to detect a difference in HbA1c after 26 weeks of treatment with Liraglutide or placebo.", 
            "measure": "HbA1c", 
            "safety_issue": "No", 
            "time_frame": "26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753362"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kaleida Health", 
            "investigator_full_name": "Paresh Dandona, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "difference from baseline in mean weekly glucose concentrations", 
            "safety_issue": "No", 
            "time_frame": "26 weeks"
        }, 
        "source": "Kaleida Health", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kaleida Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}